This study is in progress, not accepting new patients
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated
- ID
- NCT05033080
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 436 people participating
- Last Updated